Literature DB >> 24672212

Pharmaceutical approval update.

Marvin M Goldenberg.   

Abstract

Obinutuzumab (Gazyva) for chronic lymphocytic leukemia; ibrutinib (Imbruvica) for mantle-cell lymphoma; and sofosbuvir (Sovaldi) for chronic hepatitis C infection.

Entities:  

Year:  2014        PMID： 24672212      PMCID： PMC3956381     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  1 in total

1.  Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Authors:  Idit Sagiv-Barfi; Holbrook E Kohrt; Laura Burckhardt; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.